Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Glaucoma, Business and Innovation, Health Economics and Policy, Practice Management

The Long Haul

The sustained-release bimatoprost implant – marketed by the trade name of Durysta – is indicated for open angle glaucoma and ocular hypertension patients who require intraocular pressure reduction. Following the FDA approval of this new drug delivery system in March 2020, we talk to three glaucoma surgery gurus: Felipe Medeiros, who was the lead investigator in the bimatoprost implant’s clinical trials, as well as E. Randy Craven and I. Paul Singh, who view the technology as a practice-changing innovation. The big question: will glaucoma treatment be transformed? 

Let us know what your experience with the sustained-release implant has been like.



Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Authors

Felipe Medeiros

Distinguished Professor of Ophthalmology and Vice-Chair for Technology, Director Clinical Research Unit, Department of Ophthalmology, Duke University, Durham, North Carolina, USA.


E. Randy Craven

Associate Professor of Ophthalmology at Johns Hopkins University, and Chief of Wilmer Eye Institute in Bethesda, Maryland, USA.


I. Paul Singh

I. Paul Singh is President of The Eye Centers of Racine & Kenosha, Wisconsin, USA. Singh reports that he is a consultant for Ellex.

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Most Popular

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register